{"preliminary_commentary":{"by_channel":{"x_thread":15,"podcast":14,"youtube":12},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03523585\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"DESTINY-Breast02","nct_id":"NCT03523585","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-breast02-nct03523585. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a","label":"Trastuzumab deruxtecan (DS-8201a)","type":"EXPERIMENTAL"},{"description":"HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine","label":"Trastuzumab+capecitabine","type":"ACTIVE_COMPARATOR"},{"description":"HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine","label":"Lapatinib+capecitabine","type":"ACTIVE_COMPARATOR"}],"collaborators":["Daiichi Sankyo Co., Ltd.","AstraZeneca"],"completion_date":{"date":"2025-12-23","type":"ACTUAL"},"conditions":["Breast Cancer"],"enrollment":{"count":608,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Trastuzumab deruxtecan","otherNames":["DS-8201a","T-DXd"],"type":"DRUG"},{"name":"Capecitabine","otherNames":["Investigator's Choice Comparative Therapy"],"type":"DRUG"},{"name":"Lapatinib","otherNames":["Investigator's Choice Comparative Therapy"],"type":"DRUG"},{"name":"Trastuzumab","otherNames":["Investigator's Choice Comparative Therapy"],"type":"DRUG"}],"last_update":"2026-02-27","lead_sponsor":"Daiichi Sankyo","official_title":"A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-06-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine","timeFrame":"Baseline up to 46 months postdose"}],"references":[{"citation":"Andre F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, Lima JP, Aksoy S, Gavila Gregori J, De Laurentiis M, Bianchini G, Roylance R, Miyoshi Y, Armstrong A, Sinha R, Ruiz Borrego M, Lim E, Ettl J, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Gambhire D, Cathcart J, Wu C, Chu C, Egorov A, Krop I. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 May 27;401(10390):1773-1785. doi: 10.1016/S0140-6736(23)00725-0. Epub 2023 Apr 20.","pmid":"37086745","type":"RESULT"},{"citation":"Fehm T, Cottone F, Dunton K, Andre F, Krop I, Park YH, De Laurentiis M, Miyoshi Y, Armstrong A, Borrego MR, Yerushalmi R, Duhoux FP, Takano T, Lu W, Egorov A, Kim SB. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024 May;25(5):614-625. doi: 10.1016/S1470-2045(24)00128-1.","pmid":"38697155","type":"RESULT"}],"start_date":{"date":"2018-08-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]","url":"https://clinicaltrials.gov/study/NCT03523585"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-breast02-nct03523585"}